Decoy Therapeutics plans Phase 1 and Phase 2a clinical trials and is listed on the Nasdaq Stock Market.
1 report, 1 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Decoy Therapeutics plans Phase 1 and Phase 2a clinical trials and is listed on the Nasdaq Stock Market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Economic Area
area of the European Union's internal market and some of EFTA states established in 1994
-
Nasdaq
American fully electronic stock exchange
Related events
- Decoy Therapeutics was listed on the Nasdaq stock exchange on September 22, 2026.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.